Evaluate Vantage
2022 Preview


Evaluate Vantage®
REPORT DOWNLOAD
Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad support from investors. However, it also means heightened scrutiny, particularly for those that are making billions from successful pandemic vaccines and treatments.
The Evaluate Vantage 2022 Preview explores the advances biopharma could make in the Covid-19 battle next year, along with key developments in the regulatory climate and innovation landscape, and the world of money, markets and M&A.